Skip to main content
. Author manuscript; available in PMC: 2020 Sep 4.
Published in final edited form as: Exp Hematol. 2019 Jun 29;75:64–73.e4. doi: 10.1016/j.exphem.2019.06.474

Figure 3.

Figure 3.

Survival analysis of AML patients with respect to CD97 expression after stratification based on cytogenetic status. (A) Overall survival of AML patients with CD97 high (Z score ≥1) versus CD97 low (Z score <1) in cytogenetically abnormal (CA-AML) patients. (B) Overall survival of AML patients with CD97 high (Z score ≥1) versus CD97 low (Z score <1) in cytogenetically normal (CN-AML) patients. (C) Disease-free survival of AML patients with CD97 high (Z score >1) versus CD97 low (Z score <1) in CA-AML patients. (D) Disease-free survival of AML patients with CD97 high (Z score ≥1) versus CD97 low (Z score <1) in CN-AML patients.